CAT and SOD activities of VA13 were increased by 28% and 53% under MDS and 70% and 105% under SDS conditions, whereas CAT and SOD activities of VA15 were increased by 48% and 64% under MDS and 76% and 94% under SDS conditions, respectively compared to control treatment. This evidence concerns the gene CAT and myelodysplastic syndrome.